Novo Nordisk A/S (NVO) — closed signal from May 27, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 25, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$42.17 – $44.07Entry zone — fair-value band
$44.13Published — price the day we called it
$47.50Target — the price the thesis aimed for
$51.46Peak — highest point inside the window, not a realized return
$48.66Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 35 days.
Peak price
$51.46
peak on July 29, 2026 — not a realized returnPeak gain
+16.6%
peak, from the publication priceWindow close
$48.66
end-of-window price, context onlyDays to target
35
Window
May 27, 2026 – August 25, 2026
The thesis — published May 27, 2026
Predicted growth
+9%
over the measurement windowTarget price
$47.50
the price the thesis aimed forEntry zone
$42.17 – $44.07
the fair-value band we waited forPrice at publication
$44.13
published May 27, 2026Confidence
81%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk combines steady growth with strong profits and a lower valuation than some peers. New clinical news around CagriSema, zenagamtide and cardiometabolic data could spark short-term interest. A recent earnings miss and higher debt reduce conviction, but oversold price action and better sentiment make a rebound in the next 0-3 months plausible.
Primary drivers
- Clinical presentations can renew interest in cardiometabolic growth
- Leading GLP-1 position supports steady demand in diabetes and obesity
- Lower valuation offers some downside protection versus richer peers
- Oversold price action can enable a tactical rebound if support holds
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.